ACVR1C

(redirected from ALK7)

ACVR1C

A gene on chromosome 2q24.1 that encodes activin receptor type IC, a receptor that forms a complex with other type-I and two type-II transmembrane serine/threonine kinase receptors for activin, a dimeric growth and differentiating factor belonging to the TGF-beta superfamily of structurally related signalling proteins. After activin binding, type-I receptors phosphorylate cytoplasmic SMAD transcription factors, which then translocate to the nucleus and interact directly with DNA or in complex with other transcription factors, playing roles in cell differentiation, growth arrest and apoptosis.
References in periodicals archive ?
SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol.
SB431542 is a selective and potent inhibitor of the TGF-[beta] pathway through suppression of the activin A receptors ALK5, ALK4, and ALK7. A83-01 is also a selective inhibitor of ALK5, ALK4, and ALK7 but is more potent than SB431542 in its inhibition and effectively blocks phosphorylation of Smad2.
Callahan et al., "SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7," Molecular Pharmacology, vol.
Callahan et al., "SB-431542 is a potent and specific inhibitor of transforming growth factor-[beta] superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7," Molecular Pharmacology, vol.
Peng was among a team of researchers that discovered a receptor, ALK7, that induces cell-death in epithelial ovarian cancer cells.
SB431542 blocks SMAD2/3 phosphorylation and nuclear translocation by inhibiting the activation of the transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7 [34].
The specific inhibition of the activin and nodal receptors, Alk4 and Alk7, and the TGF[beta] receptor, Alk5, avoids Smad2/Smad3 phosphorylation and the subsequent initiation of downstream signalling [90].
SB431542 destroys the Lefty/Activin/TGFb pathways by inhibiting activities of ALK4, ALK5, and ALK7 receptors [14].
Ding and colleagues introduced A83-01, a selective inhibitor of TGF-betaRI, ALK4, and ALK7, to generate rat and human iPSCs with a self-renewal state closer to mouse ES cells [26].